Unibest

Pharmaceutical intermediates

Lifitegrast Intermediates

4 pharmaceutical intermediates for Lifitegrast. Indication: Dry Eye Syndromes.

Submit a ProjectAll intermediates

About Lifitegrast

Originator
Shire Development Llc
Indication
Dry Eye Syndromes
Approved Date
07/11/2016
DS/DP
03/10/2025

Available intermediates

4 intermediates currently listed for Lifitegrast. Request specifications, documentation or a quotation for any item below.

Lifitegrast intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
benzofuran-6-carboxylic acid77095-51-3//
2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid851784-82-2//
5,7-Dichloro-1,2,3,4-Tetrahydroisoquinoline-6-Carboxylic Acid Hydrochloride1289646-93-0//
methyl (S)-2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride851785-21-2//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Lifitegrast?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →